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Summary
Evidence for the health impact of obesity has largely focussed on adults. We estimated
the population prevalence and prevalence ratio of obesity‐associated comorbidities in
children and adolescents aged 5 to 18 years. Five databases were searched from
inception to 14 January 2018. Population‐based observational studies reporting
comorbidity prevalence by weight category (healthy weight/overweight/obese) in
children and adolescents aged 5 to 18 years from any country were eligible.
Comorbidity prevalence, stratified by weight category, was extracted and prevalence
ratios (relative to healthy weight) estimated using random effects meta‐analyses. Of
9183 abstracts, 52 eligible studies (1 553 683 participants) reported prevalence of
eight comorbidities or risk markers including diabetes and nonalcoholic fatty liver
disease (NAFLD). Evidence for psychological comorbidities was lacking. Meta‐analyses
suggested prevalence ratio for prediabetes (fasting glucose ≥ 100 mg/dL) for those
with obesity relative to those of a healthy weight was 1.4 (95% confidence interval
[CI], 1.2‐1.6) and for NAFLD 26.1 (9.4‐72.3). In the general population, children and
adolescents with overweight/obesity have a higher prevalence of comorbidities relative
to those of a healthy weight. This review provides clinicians with information when
assessing children and researchers a foundation upon which to build a comprehensive
dataset to understand the health consequences of childhood obesity.
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1 | INTRODUCTION
Obesity is a major global epidemic impacting approximately 20% of
the population and costing $2.0 trillion.1,2 In adults, there is a range
of known physical and psychological obesity‐related comorbidities
including coronary heart disease, type 2 diabetes, hypertension,
dyslipidaemia, pulmonary disorders, depression, and some cancers.3,4
Studies in children have largely focused on the link to increased risk
of obesity as adults.5,6 However, there is increasing evidence that
paediatric populations are also susceptible to a range of physical and
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psychological obesity‐related comorbidities, including type 2 diabetes
and depression.7-14
Given the extent of the global obesity epidemic, the impact on an
individual's health, and the cost to health care systems and global
economies, it is important to identify obesity‐related comorbidities in
childhood to aid early identification and treatment.15
There is currently limited information comparing the relative
frequency of obesity‐related comorbidities among children with
overweight or obesity relative to healthy‐weight individuals. Previous
systematic reviews have either not included children under 14 years,16
have included data from specific clinical populations,17 or were limited
to specific countries.18 Furthermore, none of the previous reviews
included meta‐analyses, instead solely providing narrative review. Thus,
it is difficult to compare and interpret the prevalence of comorbidities
between weight categories. We aimed to identify population‐based
research that identified any obesity‐associated comorbidity in children
and adolescents aged 5 to 18 years and to estimate the prevalence
and prevalence ratio of each comorbidity using meta‐analyses.
2 | METHODS
2.1 | Search strategy and selection criteria
MOOSE guidelines for reporting systematic reviews of observational
data were considered to structure the search, conduct, and report
the review.19 The search strategy aimed to identify articles providing
the prevalence of any type of obesity‐associated comorbidity reported
in children and adolescents aged 5 to 18 years. A search was conducted
of MEDLINE, MEDLINE in Process, EMBASE, PsycINFO, and Web of
Science since the date of inception to January 2018. MESH and
free‐text terms were grouped into four categories (prevalence,
obesity, comorbidities, and childhood). We included free‐text terms
of specific comorbidities, such as type 2 diabetes, depression,
self‐esteem, and sleep disorders, to increase the specificity of the
results, but the search was not limited to these. An example search
strategy is provided in Data S2.
Manuscripts were eligible for inclusion if they reported
observational study designs that provided prevalence (or data
allowing its calculation) of comorbidities by weight category (healthy
weight, overweight, and obese—based on body mass index [BMI]
percentiles), in children and adolescents aged 5 to 18 years. Studies
that included selected populations (eg, those with a history of illness
in the family or identified from hospital clinics) and participants where
obesity was a symptom of an underlying illness (eg, Prader‐Willi
syndrome, Cushing syndrome, hypothyroidism, and Hashimoto
disease) or a side effect from medication (eg, antidepressants and
antipsychotics) were excluded. Non‐English articles were only eligible
if English translations were available. Studies were eligible for
inclusion in a meta‐analysis if there were at least two studies of the
same comorbidity, in which the same definition was applied.
A sample of 693 (8%) of potentially eligible manuscripts were
reviewed independently by two reviewers (V.S. and M.B.) over four
rounds, each round indicating substantial agreement.20,21
Disagreements were resolved through discussion. Full results of
these analyses are provided in Data S3.
2.2 | Data extraction and quality assessment
Details of authors, study design, setting, sample size, participant
characteristics, and prevalence by weight category were extracted to
bespoke data collection spreadsheets. Three authors were contacted
to resolve queries regarding study design, method, and/or results;
however, no additional information was provided. Study quality was
assessed using the Joanna Briggs Institute's Critical Appraisal Checklist
using simplistic scoring (0‐5—poor quality; 6‐10—high quality).22,23
The checklist includes components for sample representativeness,
reliability of measurement, and whether sufficient details of BMI
classification and comorbidity definition were reported.
Comorbidities that were defined using different indicators (eg,
fasting plasma glucose, homeostasis model assessment for insulin
resistance [HOMA‐IR], and HbA1c as different indicators of diabetes)
were reviewed separately and only grouped for discussion. Similarly,
manuscripts presenting data using differing cut‐offs to define a
comorbidity were separated in the analysis. Data were extracted by
weight category (healthy weight: <85th percentile; overweight:
≥85th and <95th percentile; and obese: ≥95th percentile) to enable
comparison between these subgroups.
2.3 | Statistical methods
Crude prevalence of comorbidities within weight categories was
estimated for all comorbidities and indicators.
For comorbidities that were reported in at least two studies,
study‐specific prevalence ratios were plotted against the variance of
the estimate in funnel plots, to illustrate variability between studies and
assess publication bias through informal inspection. Combined
estimates of prevalence ratios and 95% confidence intervals (CIs) were
calculated using DerSimonian and Laird method for random effects
models as programmed in the Comprehensive Meta‐Analysis software
(Englewood, New Jersey).24 Forest plots for each comorbidity/indicator
allowed side‐by‐side comparison of the studies. As part of the analysis,
potential reasons for heterogeneity were identified, such as participant
or sampling differences, country of study, sample size, gender, setting,
and/or study design. The focus was directed by the availability of infor-
mation reported in the articles, eg, if prevalence was provided by gender
or age or if a number of the studies were conducted in the same country.
3 | RESULTS
3.1 | Descriptive analysis
The search identified 11 404 papers, of which 2221 were duplicates.
The resulting 9183 abstracts were screened, resulting in 52 eligible
manuscripts (1 553 683 participants) describing prevalence of obesity
comorbidities within three weight categories in population‐based
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samples (Figure 1). Nineteen papers reported the prevalence of more
than one comorbidity (or more than one population)25; these have
been grouped into eight types of comorbidity: (1) hyperglycaemia, (2)
dyslipidaemia, (3) hypertension, (4) nonalcoholic fatty liver disease
(NAFLD), (5) cardiovascular risk, (6) pulmonary disorder, (7) psycholog-
ical comorbidities, and (8) other comorbidities.
Data were gathered from 20 countries across five continents, with
the majority of studies based in Asia and Europe. While some studies
provided separate estimates for children (≤13 y) and adolescents
(≥13 y), the majority reported combined prevalence. This meant
prevalence for each subgroup (children and adolescents) could not
be estimated. Three papers reported assessing pubertal status, only
Papoutsakis et al reported prevalence by pubertal status; however,
they did not control for weight status; therefore, the impact of
weight and pubertal status on prevalence could not be deter-
mined.26-28 The remaining papers provided data according to age;
however, there was inconsistency in the cut‐offs applied, with cut‐offs
including 10 to 11, 12 to 14, and 15 to 18; <12 and ≥12; and 8 to 11
and 12 to 14.29-31
In the majority of comparisons, prevalence was reported to be
greatest in children with overweight or obesity compared with those
of a healthy weight. For most, prevalence increased with increasing
weight category. Crude prevalence estimates varied substantially
between studies (Table 1). Data S1 provides a summary of studies
reporting prevalence data, grouped by comorbidity (measure/test
and cut‐off).
Figure 2 provides a summary of meta‐analyses of prevalence ratios
for eligible comorbidities in children who were overweight or obese
FIGURE 1 Systematic review flow chart [Colour figure can be viewed at wileyonlinelibrary.com]
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relative to children of a healthy weight (individual forest plots are in
Data S4). Overall, results suggest that children with obesity have the
greatest prevalence of comorbidities; I2 statistics ranged greatly across
comorbidities.
3.2 | Hyperglycaemia
Twelve studies provided prevalence estimates for markers of
hyperglycaemia (n = 98 835), the majority of which assessed levels
of fasting glucose. While children and adolescents with obesity
regularly had the highest prevalence of hyperglycaemia, patterns were
inconsistent, and the magnitude of prevalence varied. Nine studies
(21 855 participants) used fasting plasma glucose ≥ 100 mg/dL
(≥5.6 mmol/L) to define hyperglycaemia and were included in a
meta‐analysis. Prevalence ratios for elevated fasting plasma glucose
were 1.4 (95% CI, 1.2‐1.6; I2: 0.0%) for children and adolescents with
overweight and 1.4 (95% CI, 1.2‐1.7; I2: 23.4%) for those with obesity
relative to those of healthy weight. Wang et al did not provide data
TABLE 1 Summary of studies reporting prevalence data, grouped by comorbidity (measure/test and cut‐off)
Comorbidity
Number of
Studies
Total
Sample Size
Overall
Age Range
Prevalence (%) in
Healthy Weight (n/N)
Prevalence (%) in
Overweight (n/N)
Prevalence (%) in
Obese (n/N)
Quality
Score
Range
Anxiety 1 8460 10‐18 13.1 (806/6154) 12.4 (106/858) 9.7 (52/538) 6
Asthma 3 4012 2‐22 10.9 (232/2134) 15.9 (96/603) 16.6 (133/803) 6‐7
Carotid‐intima media
thickness
1 575 11‐13 24.2 (76/314) 36.9 (66/179) 42.7 (35/82) 7
Depression 1 8640 10‐18 30.1 (1853/6154) 30.2 (259/858) 30.9 (166/538) 6
Hyperglycaemia (OGTT) 1 76 732 17‐17 <1 (7/53 684) <1 (4/9202) 0.3 (8/2897) 9
Hyperglycaemia (FPG) 10 21 855 6‐18 6.6 (806/12 152) 9.7 (274/2821) 10.5 (318/3021) 4‐10
Hyperglycaemia
(insulin resistance)
1 248 10‐12 2.2 (3/137) 1.4 (1/74) 10.8 (4/37) 5
Elevated uric acid 1 2405 6‐12 14.5 (254/1753) 28.3 (102/361) 43.6 (127/291) 7
Exercise‐induced
wheeze/cough
1 903 7‐11 0.5 (4/755) 36.9 (31/84) 68.8 (44/64) 7
Flatfoot 3 827 652 5‐19 13.5 (87 055/646 176) 17.9 (15 323/85 805) 21.8 (10 394/47 762) 4‐10
Gallstones 1 510 816 10‐19 0.1 (215/301 549) 0.2 (179/99 987) 0.3 (372/109 280) 9
Low self‐esteem 1 2491 9‐14 4.5 (86/1905) 8.9 (32/359) 14.5 (33/227) 4
High blood pressure
(>90 percentile)
24 136 144 1‐20 3.1 (2928/94 803) 6.5 (1336/20 478) 17.9 (3726/20 863) 4‐9
Low HDL cholesterol 7 18 352 6‐18 8.1 (433/5316) 15.7 (347/2215) 20.3 (400/1968) 4‐9
High C‐reactive protein 1 575 11‐13 2.6 (8/306) 15.5 (24/155) 32.3 (20/62) 4
High triglycerides 7 15 405 2‐19 4.2 (236/5598) 12.6 (213/1693) 19.2 (383/1997) 4‐9
High LDL cholesterol 2 1113 9‐15 3.9 (23/597) 7.5 (22/294) 12.2 (27/222) 4‐5
Lower back pain 1 966 10‐16 46.7 (344/736) 47.2 (84/178) 53.9 (28/52) 8
Metabolic syndrome
(Cook et al)
2 2732 7‐18 0.9 (18/1886) 1.8 (7/400) 19.1 (85/446) 7
Metabolic syndrome
(de Ferranti et al)
1 2761 15‐19 0.3 (3/1049) 1.4 (4/289) 20.8 (75/360) 7
Metabolic syndrome (IDF) 6 18 792 6‐18 0.7 (48/6970) 6.7 (190/2830) 20.4 (586/2868) 4‐9
Metabolic syndrome (NCEP) 6 8705 6‐18 0.5 (28/5204) 9.2 (148/1617) 32.8 (598/1825) 5‐10
NAFLD (ultrasound) 5 5305 6‐18 2.6 (90/3495) 10.9 (115/1059) 46.7 (309/662) 4‐7
NAFLD (elevated ALT) 2 643 6‐18 0.6 (2/322) 6.2 (8/130) 25.7 (49/191) 8‐9
NAFLD (elevated AST) 1 496 14‐17 4.3 (16/376) 10.9 (10/92) 17.9 (5/28) 9
Obstructive sleep apnoea 1 966 10‐16 2.0 (15/736) 3.4 (6/178) 3.9 (2/52) 8
High total cholesterol 4 4484 6‐16 12.4 (383/3086) 11.6 (97/833) 17.9 (101/565) 4‐8
Traumatic dental injuries 2 2565 6‐13 12.8 (243/1892) 12.1 (54/445) 13.6 (31/228) 8
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; FPG, fasting plasma glucose; HDL, high‐density lipoprotein; IDF, International
Diabetes Federation; LDL, low‐density lipoprotein; NAFLD, nonalcoholic fatty liver disease; NCEP, National Cholesterol Education Program; OGTT, oral
glucose tolerance test.
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controlling for pubertal status.26 Two of the remaining eight studies
considered children aged 6 to 13 years; however, the reported preva-
lence ranged from 3.4% to 29% in the group with obesity.32,33
3.3 | Dyslipidaemia
Prevalence of dyslipidaemia was available from 19 studies, assessed
by multiple markers (high‐density lipoprotein [HDL], low‐density
lipoprotein [LDL], triglyceride [TG], and total cholesterol) in nine
distinct populations, with 18 844 participants. Overall, dyslipidaemia
was consistently greater in children with obesity, and there was an
overall increase in prevalence with increasing weight category, but
crude prevalence estimates varied from 1% to 23% in children and
adolescents of healthy weight and 0% to 62% in those with obesity.
Prevalence ratios for high total cholesterol (1.7 [95% CI, 1.1‐2.7; I2:
48.6%]), low HDL (2.9 [95% CI, 2.1‐4.1; I2: 78.6%]), high LDL
(3.3 [95% CI, 1.6‐6.8; I2: 35.6%]), and high TGs (4.2 [95% CI,
3.1‐5.6; I2: 56.2%]) indicated consistently greater prevalence of
dyslipidaemia in children and adolescents with obesity compared
with those of a healthy weight. Analogous estimates of prevalence
ratios for children with overweight were closer to one but mostly
significant (see Table 1). Tandon et al and Minghelli et al considered
similarly aged participants, 10‐ to 18‐ and 10‐ to 16‐year‐olds,
respectively; however, the reported prevalence was considerably
different, 61.5% and 0% in those with obesity, respectively.34,35
Although it should be noted that Minghelli et al only recruited
52 participants with obesity, therefore, the prevalence may be
a factor of the small group size.
3.4 | Cardiovascular risk factors
Cardiovascular risk was investigated by one study using carotid‐intima
media thickness and in 14 studies comparing the prevalence of
metabolic syndrome according to four different definitions.
Prevalence estimates were high overall in children/adolescents with
overweight and obesity and were highest in children/adolescents with
obesity (majority greater than 20%). Only studies reporting metabolic
syndrome (n = 13, 28 922 participants) were included in the
meta‐analysis. Compared with children and adolescents of a healthy
weight, those with obesity had prevalence ratio 21.2 (95% CI,
1.2‐381.6; I2: 94.3%), 53.9 (95% CI, 9.7‐297.9; I2: 93.7%), and 58.0
(95% CI, 27.7‐121.3; I2: 61.0%) for metabolic syndrome based on
criteria proposed by Cook et al, International Diabetes Federation
(IDF), and the National Cholesterol Education Program (NCEP),
respectively.36-38 Prevalence ratios comparing children and adolescents
with overweight to healthy‐weight children and adolescents were also
high, although lower than for those with obesity (seeTable 1).
3.5 | Hypertension
Thirty‐one studies reporting prehypertension or hypertension were
identified (n = 176 987 individuals). Crude prevalence rates were
highest in children and adolescents with overweight or obesity.
FIGURE 2 Average random effects
estimates of prevalence ratios and 95%
confidence intervals for the comorbidities/
comorbidity indicators. Left‐hand side
excludes metabolic syndrome and
nonalcoholic fatty liver disease (NAFLD)
because of differences in scale [Colour figure
can be viewed at wileyonlinelibrary.com]
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Studies used a variety of thresholds to define hypertension, including
≥90th to <95th percentile (prehypertension), ≥90th percentile, and
≥95th percentile. Individual analysis indicated similar prevalence
ratios; therefore, the data were combined to calculate the prevalence
of hypertension overall. In 29 studies, the prevalence ratio was 4.0
(95% CI, 2.8‐5.7; I2: 95.2%) in children and adolescents with obesity
compared with those of a healthy weight. Similarly, prevalence
estimates were greater in children and adolescents with overweight
than in those of a healthy weight, but lower than those with obesity
(see Table 1). Dyson et al recruited participants from India, China and
Mexico and provided prevalence data by country.25 Prevalence in
those with obesity ranged from 23% (China) to 47% (India).
3.6 | Nonalcoholic fatty liver disease
Eight studies provided prevalence of NAFLD by weight status
(n = 6444). All suggested a higher prevalence in children and adoles-
cents with obesity. Crude prevalence estimates in children and adoles-
cents of a healthy weight ranged from 0% to 6.8% compared with
4.3% to 21.3% in those who were overweight and 17.9% to 62.0%
in those with obesity. Five studies (n = 5305) that assessed NAFLD
by ultrasound were eligible for inclusion in the meta‐analysis. Com-
bined prevalence ratios for NAFLD were 26.1 (95% CI, 9.4‐72.2; I2:
91.4%) for children and adolescents with obesity and 6.1 (95% CI,
3.3‐11.2; I2: 67.9%) for those who were overweight. Two studies
recruited children of similar ages, Adibi et al 6‐ to 18‐year‐olds and
Alavian et al 7‐ to 18‐year‐olds. Both reported considerably higher
prevalence in those with obesity, 54% and 32%, compared with the
healthy‐weight group.39,40
3.7 | Pulmonary disorders
Five studies compared the prevalence of pulmonary disorders in
children and adolescents by weight status (n = 5881), three were
asthma studies (n = 4012).41-43 Meta‐analysis of the asthma studies
indicated that children and adolescents with obesity and with over-
weight had, respectively, 1.7 (95% CI, 1.4‐2.1; I2: 0.0%) and 1.6 (95%
CI, 1.2‐1.9; I2: 0.0%) times the prevalence of asthma compared with
those of a healthy weight. These studies were relatively small, of mod-
erate quality, and assessed asthma status using parent and/or self‐
report. Exercise‐induced wheeze/cough was considered in one study
(n = 903) in which prevalence in children with obesity was high
(68.8%) compared with those of a healthy weight (0.5%).44 Although
ofmoderate quality, statuswas based on self‐report andwas not eligible
for inclusion in the meta‐analysis. One study compared prevalence of
obstructive sleep apnoea (n = 966) and found increasing prevalence as
weight status increased.34
3.8 | Psychological disorders
Two studies (n = 11 088) compared psychological comorbidities and
met our eligibility criteria for inclusion into the review.29,45 Zakeri
et al (n = 8339) considered both depression and anxiety using the
Global School‐based Health Survey (GSHS).46 Franklin et al measured
low self‐esteem (n = 2749) using the Self‐perception Profile for
Children. In contrast to other comorbidities, Zakeri et al found that
the prevalence of neither depression nor anxiety differed by weight
status. Franklin et al reported the highest prevalence of low self‐
esteem in children and adolescents with obesity, though this was
considered of poor quality according to the Joanna Briggs Institute's
Critical Appraisal Tool.
3.9 | Less established comorbidities
We identified studies of five less established comorbidities/indicators,
including high C‐reactive protein, elevated uric acid, gallstones, low
back pain, and traumatic dental injuries. Although there was consider-
able variation in reported prevalence, for most studies, prevalence was
highest in children and adolescents with obesity. Two comorbidities,
traumatic dental injuries and flatfoot, met criteria for inclusion in the
meta‐analysis. The prevalence of traumatic dental injuries did not dif-
fer by weight status (n = 2565).47,48 Children and adolescents with
obesity had a 1.8 (95% CI, 1.4‐2.3; I2: 71.5%) greater prevalence of
flatfoot than those of a healthy weight.49,50
4 | DISCUSSION
Our systematic review identified 52 eligible studies involving
1 553 683 participants, reporting eight comorbidities or risk markers
including diabetes, hypertension, dyslipidaemia, and NAFLD, which
could be included in meta‐analysis. The results suggested that children
and adolescents with obesity had a higher prevalence of the majority
of the identified comorbidities, relative to those of healthy weight.
The review indicated that there were small to large increases in
prevalence between weight categories for most comorbidities. Meta‐
analyses suggested children and adolescents with obesity were 1.4
times more likely to have prediabetes, 4.4 times more likely to have
high blood pressure, 26.1 times more likely to have NAFLD, and 1.7
times more likely to have self‐reported asthma. Although the preva-
lence ratios for metabolic syndrome were high, the prevalence among
healthy‐weight children and adolescents was very low (at most 1%)
and the results are likely to be inflated because of obesity forming part
of the criteria for diagnosis.36
Results from previous systematic reviews supported our findings
to some degree.16-18 Additionally, we identified an increase in the risk
of NAFLD and carotid‐intima media thickness in children and adoles-
cents with obesity that had not been previously identified by some
or all of the previous reviews. The prevalence of NAFLD is particularly
concerning, as it is regarded as a silent disease with a propensity to
fibrosis and cirrhosis.51
Other reviews identified other comorbidities, for example, Guh
et al found a number of cancers associated with obesity (eg, colorectal,
kidney, prostate, breast, and ovarian). However, the review of Guh
et al was not limited to children and the estimates for cancer
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predominantly considered participants aged 40 years and older in
whom cancers are more prevalent. Furthermore, cancers tend to have
long latent periods and the ones identified are rare in childhood.52
Despite the current results suggesting a higher prevalence of
comorbidities in those with obesity, the association between weight
status and prevalence of comorbidities was often difficult to ascertain
because of between‐study heterogeneity. In the current systematic
review, there was a lack of consistency between studies in definitions
and cut‐offs for comorbidities. For high blood pressure, three cut‐offs
were identified (≥90th percentile, ≥90th and <95th percentile, and
≥95th percentile), and for low HDL cholesterol, both <40 and
≤40 mg/dL were used in studies. However, for both of these comor-
bidities, studies with different cut‐offs were combined into one group,
since the prevalence ratios for each definition were comparable. For
metabolic syndrome, however, it was not appropriate to combine
definitions for analysis because of heterogeneity in prevalence ratios
between different definitions. Currently, there is no consensus on
the definition of metabolic syndrome, and different definitions
resulted in heterogeneous population prevalence, limiting the ability
to obtain a single estimate.53
There was also considerable variation in study sample sizes, which
can influence the reported prevalence (smaller groups are subject to
greater sampling variance, which would impact the accuracy of the
prevalence ratio estimates). This was controlled for to some extent
in the meta‐analysis, in which smaller studies were given less weight
than larger studies.54
4.1 | Strengths and limitations
To our knowledge, we have conducted the first international system-
atic review and meta‐analyses considering the prevalence of comor-
bidities in children and adolescents with overweight or obesity
relative to those of a healthy weight. Our systematic review and meta‐
analyses followed a predefined protocol, which explicitly detailed the
inclusion and exclusion criteria for the studies and the steps undertaken
in each stage. The search criteria included multiple observational study
designs that enabled greater sensitivity in detecting relevant literature
in order to develop an exhaustive list of obesity‐related comorbidities.
This was a limitation of previous systematic reviews in the area.16-18
We conducted a sensitive review with scope to identify any type of
comorbidity, and thus, we were not restricted to reporting prevalence
rates of a confined set of comorbidities, which may have omitted key
findings in important disease areas.
Some limitations areworthy of consideration. Firstly, it is recognised
that pubertal stage is an important factor when determining the
prevalence of comorbidities. O'Hara et al estimated the prevalence
of cardiometabolic risk factors in children aged 3 to 19 years and
reported a positive association between age and prevalence.55,56
Despite this, themajority of studies in the current reviewdid not control
for age or pubertal status when providing prevalence estimates by each
group. This meant prevalence data for growth or age subgroups could
not be estimated. Further, papers that did provide data by age were
inconsistent in the cut‐offs applied. Secondly, only a small number of
articles pertaining to psychological comorbidities were identified and
these used imperfect measures of these constructs. It is possible that
other articles may have been identified through a more specific search.
However, it may also be indicative of a lack of prevalence studies in this
population. Thirdly, studies related to all psychological comorbidities
and some physical, utilised self‐report questionnaires, some of which
were not validated. This has the potential to hinder the accuracy of
the data, because of self‐report bias and nonspecific tests, and reduced
the generalisability of the results. That said, it should be noted that, at
present, alternative screening methods for many of these comorbidities
are not available. Finally, non‐English language articles were not
included in the review, potentially excluding relevant articles and
impacting the accuracy of prevalence estimates and the generalisability
of the results. However, previous reviews have offered conflicting
information about the impact of language restrictions on results, with
some suggesting that translation was inefficient and did not yield
appreciably different results.57-60 All non‐English articles were retained
in a separate Endnote folder for possible future research (available
upon request).
Other evidence has reported positive associations between child-
hood and obesity‐associated comorbidity prevalence; many of which
have severe implications if left unmanaged.61-66 The results of the
meta‐analysis highlight the need to address children and adolescents
with obesity given the alarming presence of ill health that can be seen
andwhich is likely to continue and exacerbate into adulthood. Research
has indicated that the long‐term health consequences can be reduced if
children with obesity go on to become healthy‐weight adults.67
The review addresses the limitations of previous systematic reviews
and provides population prevalence estimates using global literature.
This consolidation of child and adolescent obesity‐associated comor-
bidity literature provides clinicians with clear and concise information
when assessing the health of children and provides researchers a
foundation upon which to build a comprehensive dataset to under-
standing the health consequences of childhood obesity. Moreover,
the review identifies gaps in existing research, such as the lack of
data by age or pubertal status, which future research can address
to improve the accuracy and generalisability of future prevalence
estimates. Finally, given the reported prevalence and potential long‐
term implications to health and well‐being, these data can also be used
to support the need for development of effective obesity treatment
and prevention strategies at a national and local level.
There are some recommendations for future research. Firstly, we
recommend that studies measure and report data by pubertal status
to better understand the impact of pubertal status on comorbidity
prevalence. Secondly, additional research in general populations,
stratified by weight category, is required to obtain an understanding
of the impact of increased weight on the prevalence, severity, and
reversibility of these comorbidities in children and adolescents.
Thirdly, additional population‐based research is required to enable
generalisability of the results beyond the study sample and to enhance
between‐study homogeneity and enable more accurate population
prevalence ratio estimates to be calculated.
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